The short version of incretin fits in a sentence. The long version — which is the one that helps — is below.
Reviewed 2025-11-14. Anything still debated is marked as such rather than presented as settled.
Retatrutide is an investigational synthetic peptide that acts on three receptor targets at once: glucose-dependent insulinotropic polypeptide, glucagon-like peptide-1, and glucagon. It is developed by Eli Lilly and appears in the literature and in trial registries under the code LY3437943. The molecule belongs to a class of engineered peptides designed to resist rapid breakdown and permit infrequent subcutaneous administration. No regulatory agency has approved it for clinical use, and all available human data come from controlled trials rather than from routine practice.
The intended pharmacology combines three signals in one molecule. GLP-1 receptor activation reduces appetite and slows gastric emptying, effects already exploited by approved incretin-based therapies. GIP receptor engagement is associated with improved insulin sensitivity and with direct effects on adipose tissue, although how much it contributes to overall outcomes is still debated. Glucagon receptor agonism raises energy expenditure and supports hepatic lipid handling, a mechanism that also tends to increase glucose output. The triple profile is hypothesized to produce a larger metabolic effect than single or dual agonism, but the relative weight of each receptor in humans is not settled.
Human evidence remains limited to controlled studies. A phase 2 trial in adults with obesity reported large, dose-dependent reductions in body weight over 48 weeks, with gastrointestinal events as the most frequently recorded adverse effect. Phase 3 programs designated TRIUMPH, for obesity, and TRANSCEND, for type 2 diabetes, are intended to confirm efficacy and to characterize safety in larger populations. Related studies are examining conditions such as knee osteoarthritis in people with obesity and metabolic liver disease. Open questions include long-term tolerability, effects on lean mass, and what happens after treatment is stopped.
Material handling focuses on limiting degradation. Lyophilized powder is generally stored at reduced temperature, often around minus twenty degrees Celsius, protected from light and moisture. Once dissolved, the peptide is less stable and is commonly kept cold and used within a short window. Repeated freeze-thaw cycles promote aggregation and should be avoided. Buffers and pH influence stability, and solution conditions are usually selected to keep the peptide near neutral pH where degradation proceeds more slowly. These practices apply to laboratory reference material, not to clinical preparations.
Verification of research-grade material depends on documentation supplied with a sample. A certificate of analysis lists purity, identity, and the methods used to establish each value. Buyers comparing suppliers look at chromatographic purity figures, mass confirmation data, and whether methods are described in enough detail to be reproduced. Independent testing can confirm reported values but adds cost and time. Because the research chemical market is not uniformly regulated, provenance and documentation quality vary widely, and claims should be evaluated against raw data rather than summary labels.
| Property | Value | Notes |
|---|---|---|
| Compound class | Synthetic triple-agonist peptide | Single linear chain carrying three receptor activities |
| Reported molecular weight | Approximately 4731 Da | Calculated from the published sequence; sources vary slightly |
| Appearance | White to off-white lyophilized powder | Typical of purified research-grade peptides |
| Solubility | Freely soluble in water; poorly soluble in nonpolar solvents | Dissolves in aqueous buffer near neutral pH |
| Storage of dry powder | -20 °C or below, desiccated, protected from light | Avoid repeated temperature cycling |
Clinical development has progressed through phase 2 trials in adults with obesity and type 2 diabetes, with phase 3 programs reported as ongoing. Reported outcomes include reductions in body weight and improvements in glycemic measures over defined treatment periods. Whether these effects translate into durable benefits after treatment ends remains an open question. Long-term safety data across broad populations are not yet complete, and regulatory decisions have not been announced.
Retatrutide is an investigational synthetic peptide engineered to activate three distinct hormone receptors within a single molecule. It targets the glucose-dependent insulinotropic polypeptide receptor, the glucagon-like peptide-1 receptor, and the glucagon receptor simultaneously. This triagonist design distinguishes it from earlier incretin-based compounds that act on one or two of these pathways. Structural modifications relative to native gut hormones extend its residence time in circulation. The molecule remains under clinical evaluation and is not approved for any indication.
Receptor activation produces downstream effects that differ by tissue. GLP-1 receptor signaling influences appetite regulation and insulin secretion in a glucose-dependent manner. GIP receptor activity contributes to metabolic handling of nutrients and may modulate adipose tissue. Glucagon receptor engagement raises energy expenditure and promotes hepatic lipid turnover, though the balance among these actions in humans is still being characterized. Preclinical models showed reductions in body weight and improved glycemic markers.
Stability depends strongly on physical state. Dry powder is comparatively robust when held at -20 °C or below, desiccated and shielded from light; under those conditions degradation is slow and measured over years. Once dissolved, the peptide becomes far more vulnerable: backbone hydrolysis, oxidation of susceptible residues and aggregation all proceed faster in solution, and the rates climb with temperature and with pH far from neutral. Refrigerated storage at 2–8 °C extends usable life for short periods, and repeated freeze–thaw cycles are best avoided.
Identity and purity are established by instrumental methods rather than by appearance. Reversed-phase high-performance liquid chromatography separates the peptide from related impurities and yields a purity value, usually expressed as the share of total peak area. Mass spectrometry checks that the observed mass agrees with the mass calculated from the published sequence, while peptide mapping or amino acid analysis adds structural evidence. Water content, counter-ion identity and residual solvents are sometimes reported as well. A certificate of analysis should name the method behind each figure, because results are method-dependent.
Solid peptide is generally held as a lyophilised powder at low temperature to slow degradation, with desiccant to limit moisture uptake. Reconstituted solutions are less stable and are usually kept refrigerated and protected from light for short periods. Repeated freeze-thaw cycles are avoided because they encourage aggregation. Laboratory handling includes work in a fume hood or laminar flow cabinet to limit inhalation and contamination. Weighing and transfer steps are performed with antistatic tools to reduce static-driven loss of fine powder.
Characterising a peptide of this size relies on a combination of chromatographic and mass spectrometric techniques. Reversed-phase high-performance liquid chromatography separates the intact molecule from related impurities, while electrospray mass spectrometry confirms molecular mass and detects truncation or oxidation products. Peptide mapping after enzymatic digestion verifies the amino acid sequence and locates modified residues. Because the molecule carries a lipid chain, assays must also distinguish the correctly conjugated product from incompletely acylated species.
== Cartridges == The stationary phase comes in the form of a packed syringe-shaped cartridge, a 96 well plate, a 47- or 90-mm flat disk, or a microextraction by packed sorbent (MEPS) device, a SPE method that uses a packed sorbent material in a liquid handling syringe. These can be mounted on its specific type of extraction manifold. The manifold allows multiple samples to be processed by holding several SPE media in place and allowing for an equal number of samples to pass through them simultaneously. In a standard cartridge SPE manifold up to 24 cartridges can be mounted in parallel, while a typical disk SPE manifold can accommodate 6 disks. Most SPE manifolds are equipped with a vacuum port, where vacuum can be applied to speed up the extraction process by pulling the liquid sample through the stationary phase. The analytes are collected in sample tubes inside or below the manifold after they pass through the stationary phase. Solid phase extraction cartridges and disks can be purchased with several stationary phases, each of which separates analytes depending on different chemical properties. The basis of most stationary phases is silica that has been bonded to a specific functional group. Some of these functional groups include hydrophobic alkyl or aryl chains of variable length (for reversed phase), quaternary ammonium or amino groups (for anion exchange), and aliphatic sulfonic acid or carboxyl groups (for cation exchange).
== Recent developments == Improvements in structural alignment methods constitute an active area of research, and new or modified methods are often proposed that are claimed to offer advantages over the older and more widely distributed techniques. A recent example, TM-align, uses a novel method for weighting its distance matrix, to which standard dynamic programming is then applied. The weighting is proposed to accelerate the convergence of dynamic programming and correct for effects arising from alignment lengths. In a benchmarking study, TM-align has been reported to improve in both speed and accuracy over DALI and CE. Other promising methods of structural alignment are local structural alignment methods. These provide comparison of pre-selected parts of proteins (e.g. binding sites, user-defined structural motifs) against binding sites or whole-protein structural databases. The MultiBind and MAPPIS servers allow the identification of common spatial arrangements of physicochemical properties such as H-bond donor, acceptor, aliphatic, aromatic or hydrophobic in a set of user provided protein binding sites defined by interactions with small molecules (MultiBind) or in a set of user-provided protein–protein interfaces (MAPPIS). Others provide comparison of entire protein structures against a number of user submitted structures or against a large database of protein structures in reasonable time (ProBiS).
=== Criminal forensics === GC–MS can analyze the particles from a human body in order to help link a criminal to a crime. The analysis of fire debris using GC–MS is well established, and there is even an established American Society for Testing and Materials (ASTM) standard for fire debris analysis. GCMS/MS is especially useful here as samples often contain very complex matrices, and results used in court need to be highly accurate.
This article was submitted to WikiJournal of Medicine for external academic peer review in 2021 (reviewer reports). The updated content was reintegrated into the Wikipedia page under a CC-BY-SA-3.0 license (2021). The version of record as reviewed is: Kholhring Lalchhandama; et al. (2021). "History of penicillin" (PDF). WikiJournal of Medicine. 8 (1): 3. doi:10.15347/wjm/2021.003. Wikidata Q107303937.
Sources: en.wikipedia.org
== Bibliography == Griffiths, John (2011). Tea: A History of the Drink that Changed the World. London: Carlton Publishing. pp. 16,18,63, 78–79, 106. Hale, Sarah Josepha Buell (1841). Early American Cookery. Boston: The Good Housekeeper. p. 112. Heiss, M.L and Heiss, R.J. (2007). The Story of Tea: A cultural history and drinking guide. Berkeley, CA: 10 Speed Press. p. 80. Mair, Victor and Hoh, Erling (2009). The true history of tea. New York: Thames and Hudson. p. 201. Stern, Tracy (2007). Tea Party: 20 Themed Tea parties with recipes for every occasion, from fabulous showers to intimate gatherings. New York: Random House. pp. 12–18.
In November 2021, CleanTechnica reported that Tesla would be opening Superchargers at 26 Buc-ee's locations in seven states. As of February 2023, there were operational Superchargers at more than half of the planned locations including in Alabama (Leeds and Robertsdale); Florida (St. Augustine); South Carolina (Florence); Tennessee (Crossville); and Texas (Bastrop, Baytown, Ennis, Giddings, Katy, Madisonville, Melissa, New Braunfels, and Wharton). Since then, more Superchargers have been added into more locations, such as in Colorado (Berthoud); Florida (Daytona Beach); Georgia (Adalrsville and Fort Valley); Kentucky (Richmond); Tennessee (Kodak); and Texas (Denton, Fort Worth, Luling, Pearland, Royse City, Temple, Terrell, and Waller).
==== Intrinsic Ubiquitin Receptors of the Proteasome ==== Polyubiquitinated proteins are targeted to the proteasome through three identified Ubiquitin receptors: Rpn1, Rpn10, and Rpn13, that decorate the 19S RP and can direct an unstructured region of the target substrate into the N-domain of the AAA motor. Each was identified individually and characterized to bind ubiquitin.
hydrogen bond A form of electrostatic interaction between an electronegative atom and a hydrogen atom bound to a second electronegative atom. Hydrogen bonding is unique because the small size of the hydrogen atoms permits proximity of the interacting electrical charges, and may occur as an intermolecular or intramolecular force.
== Predicted protein structures == Having proposed a model of globular proteins, Wrinch investigated whether it was consistent with the available structural data. She hypothesized that bovine tuberculin protein (523) was a C1 closed cyclol consisting of 72 residues and that the digestive enzyme pepsin was a C2 closed cyclol of 288 residues. These residue-number predictions were difficult to verify, since the methods then available to measure the mass of proteins were inaccurate, such as analytical ultracentrifugation and chemical methods. Wrinch also predicted that insulin was a C2 closed cyclol consisting of 288 residues. Limited X-ray crystallographic data were available for insulin which Wrinch interpreted as "confirming" her model. However, this interpretation drew rather severe criticism for being premature. Careful studies of the Patterson diagrams of insulin taken by Dorothy Crowfoot Hodgkin showed that they were roughly consistent with the cyclol model; however, the agreement was not good enough to claim that the cyclol model was confirmed.
Sources: en.wikipedia.org
A trachea may be narrowed or compressed, usually a result of enlarged nearby lymph nodes; cancers of the trachea or nearby structures; large thyroid goitres; or rarely as a result of other processes such as unusually swollen blood vessels. Scarring from tracheobronchial injury or intubation; or inflammation associated with granulomatosis with polyangiitis may also cause a narrowing of the trachea (tracheal stenosis). Obstruction invariably causes a harsh breathing sound known as stridor. A camera inserted via the mouth down into the trachea, called bronchoscopy, may be performed to investigate the cause of an obstruction. Management of obstructions depends on the cause. Obstructions as a result of malignancy may be managed with surgery, chemotherapy or radiotherapy. A stent may be inserted over the obstruction. Benign lesions, such as narrowing resulting from scarring, are likely to be surgically excised. One cause of narrowing is tracheomalacia, which is the tendency for the trachea to collapse when there is increased external pressure, such as when airflow is increased during breathing in or out, due to decreased compliance. It can be due to congenital causes, or due to things that develop after birth, such as compression from nearby masses or swelling, or trauma. Congenital tracheomalacia can occur by itself or in association with other abnormalities such as bronchomalacia or laryngomalacia, and abnormal connections between the trachea and the oesophagus, amongst others.
Gene expression is the process by which the information contained within a gene is used to produce a functional gene product, such as a protein or a functional RNA molecule. This process involves multiple steps, including the transcription of the gene's sequence into RNA. For protein-coding genes, this RNA is further translated into a chain of amino acids that folds into a protein, while for non-coding genes, the resulting RNA itself serves a functional role in the cell. Gene expression enables cells to utilize the genetic information in genes to carry out a wide range of biological functions. While expression levels can be regulated in response to cellular needs and environmental changes, some genes are expressed continuously with little variation.
=== Rediscovery of glucagon === The hormone glucagon was discovered by C.P. Kimball and John R. Murlin in 1923 as a hyperglycaemic (blood-sugar elevating) substance among the pancreatic extracts. The biological importance of glucagon was not known and the name itself was essentially forgotten. It was a still a mystery at the time de Duve joined Bouckaert at Leuven University to work on insulin. Since 1921, insulin was the first commercial hormonal drug originally produced by the Eli Lilly and Company, but their extraction methods introduced an impurity that caused mild hyperglycaemia, the very opposite of what was expected or desired. In May 1944 de Duve realised that crystallisation could remove the impurity. He demonstrated that Lilly's insulin process was contaminated, showing that, when injected into rats, the Lilly insulin caused initial hyperglycaemia and the Danish Novo insulin did not. Following his research published in 1947, Lilly upgraded its methods to eliminate the impurity. By then de Duve had joined Carl Cori and Gerty Cori at Washington University in St. Louis, where he worked with a fellow researcher Earl Wilbur Sutherland, Jr., who later won the Nobel Prize in Physiology or Medicine in 1971. Sutherland had been working on the puzzle of the insulin-impurity substance, which he had named hyperglycemic-glycogenolytic (HG) factor. He and de Duve soon discovered that the HG factor was synthesised not only by the pancreas but also by the gastric mucosa and certain other parts of the digestive tract.
Examples of China's increasing global presence as an arms supplier in 2010–14 included deals with Venezuela for armoured vehicles and transport and trainer aircraft, with Algeria for three frigates, with Indonesia for the supply of hundreds of anti-ship missiles and with Nigeria for the supply of several unmanned combat aerial vehicles. Following rapid advances in its arms industry, China has become less dependent on arms imports, which decreased by 42 percent between 2005–09 and 2010–14. Russia accounted for 61 percent of Chinese arms imports, followed by France with 16 percent and Ukraine with 13 per cent. Helicopters formed a major part of Russian and French deliveries, with the French designs produced under licence in China. From 2021 to 2026, China's arms imports fell by 72 percent; Russia accounted for 66 percent of China's arms imports. Over the years, China has struggled to design and produce effective engines for combat and transport vehicles. It continued to import large numbers of engines from Russia and Ukraine in 2010–14 for indigenously designed combat, advanced trainer and transport aircraft, and naval ships. It also produced British-, French- and German-designed engines for combat aircraft, naval ships and armoured vehicles, mostly as part of agreements that have been in place for decades. In August 2021, China tested a nuclear-capable hypersonic missile that circled the globe before speeding towards its target.
Sources: en.wikipedia.org
It is an investigational peptide that activates three hormone receptors: GIP, GLP-1 and glucagon. It is being studied mainly for obesity and type 2 diabetes, and it is not approved for any clinical use. Published information comes from controlled trials rather than from general practice.
No. As of the most recent public information it remains investigational in every jurisdiction. Material sold under this name outside trials is a research chemical, not an approved medicine. Current status should always be checked against regulator notices.
Dual agonists act on two receptors, usually GIP and GLP-1. Retatrutide adds glucagon receptor activity, which is associated with increased energy expenditure. Whether that third component adds clinically meaningful benefit over dual agonism remains an open question.
Purity is usually reported from reversed-phase high-performance liquid chromatography with ultraviolet detection. Peak area percentage gives a purity figure, though it does not prove identity. Mass spectrometry is used alongside chromatography to confirm the expected molecular mass.